Patrick Colin

Background

About Patrick Colin

More than 37 years of overall drug development experience. Experience in large ( Bristol Myers Squibb) and mid-size pharma ( Axcan Pharma), as well as biotechs ( Purecell Technologies, GInova Pharma, Gicare Pharma,Laurent Pharma and Verlyx Pharma). Experience as well in the starting up of new firms, such as GInova Pharma Inc, Gicare Pharma inc. Giiant Pharma and Laurent Pharmaceuticals. Experience in BD of CRO services for CEE region in Europe. Experience in international Drug Development Consultin Expertise in gastroenterology, hepatology, and cystic fibrosis. Experience also is other TAs, including but not limited to: cardiology, metabolic diseases, psychiatry, infectious diseases, oncology, women's health, dermatology, and biosimilar drugs development. Additional experience in clinical research conducted in developing countries (Dominican Republic and Peru). Has managed R&D teams (N: 43) responsible for 15 market approvals (following NDA, NDS, SNDA, SNDS, MA, PMA and Class 3 Medical Devices regulatory filings) People management: was responsible for a 43 people R&D group at Axcan. People oriented and team focused. Co-founder of GInova Pharma ( GI focused biotech). Prepared all development plans ( 3 NCEs) and actively participated to the financing round ($ 15 M raised vs $ 20 M goal).Co-founder and Chief Development Officer of Gicare Pharma, a newly created GI focused biotech company. Gicare Pharma currently develops orally administered alternatives to IV sedation used in patients undergoing colonoscopy. Also co-founder of Laurent Pharma, a biotech developing drugs for the treatment of Cystic Fibrosis and COVID-19. Since 2024, VP, Clinical Development at Angany Inc, a biopharmaceutical company specialized in clinical allergy. Excellent medico-marketing skills. Speaks French and English fluently, and basic Spanish.